CXCL13 and B-cell chronic lymphocytic leukemia: Additional evidence could be provided by the findings that ibrutinib has been found to significantly reduce CXCL13-mediated CLL cell adherence to the BM and lymph node microenvironment in CLL patients, including interactions with macrophages [32, 33].